Targeting PDAC Heterogeneity

In this project, we utilize advanced preclinical models, including human organotypic slice cultures and patient-derived tumor fragments xenografted into immunocompromised
animals. Our objective is to investigate the impact of drug combinations, tailored to specific biotypes, on tumor progression. Integrating this approach with genetically modified, patient-derived in vitro co-culture models of different cell populations will permit a detailed assessment and validation of drug selectivity and reveal cellular adaptive responses within distinct tumor niches.